65710-07-8
Chemical Structure
Apramycin sulfate
Synonym(s): Nebramycin II sulfate
- CAS No.: 65710-07-8
- Formula:C21H43N5O15S
- Molecular Weight:637.66
IUPAC Name: (2R,3R,4S,5S,6S)-5-amino-2-(((2R,3S,4R,4aR,6S,7R,8aS)-7-amino-6-(((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl)oxy)-4-hydroxy-3-(methylamino)octahydropyrano[3,2-b]pyran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4-diol sulfate
InChIKey: WGLYHYWDYPSNPF-RQFIXDHTSA-N
SMILES: O[C@H]1[C@](O[C@H](O[C@@]([C@H](C[C@H]2N)N)([H])[C@@H]([C@H]2O)O)[C@H](N)C3)([H])[C@@]3([H])O[C@H](O[C@@]([C@@H]([C@@H](O)[C@@H]4N)O)([H])O[C@@H]4CO)[C@H]1NC.O=S(O)(O)=O
Biological Activity: Apramycin (EBL 1003) sulfate is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin sulfate is a potential anti-drug-resistance antibiotic[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Apramycin sulfate | 98.0% | Apramycin (EBL 1003) sulfate is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin sulfate is a potential anti-drug-resistance antibiotic. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Apramycin sulfate (Standard) | 97.09% | Apramycin (sulfate) (Standard) is the analytical standard of Apramycin (sulfate). This product is intended for research and analytical applications. Apramycin (EBL 1003) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Juhas M, et al. In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii. J Antimicrob Chemother. 2019;74(4):944-952. [Content Brief]
- [2]. Meyer M, et al. In vivo efficacy of apramycin in murine infection models. Antimicrob Agents Chemother. 2014 Nov;58(11):6938-41. [Content Brief]
- [3]. Becker K, et al. Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis. EBioMedicine. 2021 Nov;73:103652. [Content Brief]
